What is Taytulla?

Taytulla is an oral contraceptive that contains the hormones progestin and estrogen. It comes in a regiment of 24 pink soft gelatin capsules that carry the active ingredients, and four maroon soft gelatin capsules that contain no active medication. It’s considered a “low-dose” birth control pill as it contains only 20 micrograms of daily estrogen, and was found to be 96 percent effective in pregnancy prevention when taken as directed.

170,000 packs have been recalled

Women who are taking Taytulla birth control pills need to carefully examine the packages. According to a recent announcement by manufacturer Allergan, some of the products may have been packaged incorrectly, placing the placebo or inactive “blank” pills, out of order.

On May 29, 2018, Allergan implemented a voluntary recall of one lot because of this issue. About 170,000 packs of Taytulla birth control pills are subject to this recall. If a woman takes the “blank pills” early because of a packaging error, her risk of becoming pregnant increases.

The recall only covers those pills given as “free samples” by a doctor’s office.  The company plans to send notification letters out to doctors and suggested that patients who received Taytulla birth control pills from their doctors talk to them about the issue.

The pills in this particular lot have been on the market since August 2017. If you took the pills and became pregnant unintentionally, contact the Taytulla lawyers at Attorney Group today. We are currently investigating cases in which Taytulla birth control did not work as expected.

“As a result of this packaging error,” Allergan stated, “oral contraceptive capsules, that are taken out of sequence, may place the user at risk for contraceptive failure and unintended pregnancy.”

The manufacturer also noted that users may not be aware that they’re taking inactive pills at the wrong time of the month, particularly if they are new users who haven’t been on birth control therapy before.

Allergan advised consumers who used a Taytulla sample pack with lot number 5620706 to contact their physicians. The products have an expiration date of May 2019 and were distributed nationwide to healthcare providers between August 2017 and May 2018.

Time You Have to Pursue a Claim is Limited. Contact Us Today.

Drug makers have a duty to provide safe products. If there are risks of harm associated with their products, they also must provide adequate warnings. If a drug maker fails to fulfill this duty, it could be held liable in lawsuits for injuries that may result.

For more information, contact Attorney Group. You can fill out the form on this page or contact us by phone or email.